Clinical value of ⁶⁸Ga-PSMA in patients with prostate cancer and biochemical recurrence using a tri-modality PET/CT-MR (3.0 T) system with a dedicated shuttle. (#72)

8:30 AM

Omar Alonso

The halo-artifact leading to a potential false negative result of 68Ga-PSMA PET-CT.  A case report. (#73)

8:30 AM

Jairo Wagner

⁶⁸Ga-PSMA PET/CT in lesion characterisation in suspected prostate carcinoma patients. (#74)

8:30 AM

Arun Sasikumar

⁶⁸Ga-PSMA-11 PET/CT for the Staging and Risk Stratification of Chinese men with Prostate cancer (#75)

8:30 AM

Feng Wang

⁶⁸Ga-PSMA PET/CT in prostate cancer – A single centre experience from India. (#76)

8:30 AM

Arun Sasikumar

The diagnostic efficacy and clinical impact of PET-CT imaging with ⁶⁸Ga-labelled PSMA ligand HBED-CC in patients with recurrent prostate cancer (#77)

8:30 AM

Murat Tuncel

Initial experience of 68Ga-PSMA PET/CT imaging in evaluation of biochemical recurrence in prostate cancer patients. (#78)

8:30 AM

Aravintho Natarajan

An Unusual uptake of ^₆₈Ga-DKFZ-PSMA-11 activity by gall bladder during prostate cancer imaging. (#79)

8:30 AM

Dilip Boddeti

Lutetium-­177 (Lu-177) labeled EDTMP for metastatic bone pain palliation- initial experience at a tertiary care centre in India (#83)

8:30 AM

Deepa Singh

Comparative assessment of skeletal uptake on ⁶⁸Ga-PSMA PET/CT versus ¹⁸F-Fluoride PET/CT in prostate cancer (#84)

8:30 AM

Aviral Singh

¹⁷⁷Lu-PSMA radioligand therapy of prostate cancer in patients with single functioning kidney (#85)

8:30 AM

Aviral Singh

A radio-pharmaceutical kit to prepare parenteral injections of a multimodal all-organic nanovesicle for "first-in-human" clinical studies in prostate cancer. (#86)

8:30 AM

Michael S Valic

Gallium-68-PSMA-HBED-CC PET/CT in patients with biochemical recurrence after radical prostatectomy or radiation therapy: potential impact on treatment choice (#87)

8:30 AM

Roelf Valkema

The value of ⁶⁸Ga-PSMA PET/CT in prostate cancer patients (#88)

8:30 AM

Thabo Lengana

Lu-177-DKFZ- PSMA-617  treatment in castration resistant  metastatic  prostate cancer.  Report of the first case in our Institution (#89)

8:30 AM

Daniel Valenzuela

Salvage ¹⁷⁷Lu-PSMA-617 therapy for a patient with chemotherapy-naïve hormone-resistant oligometastatic prostate cancer (#90)

8:30 AM

Finn E von Eyben

Post-therapeutic dosimetry of ¹⁷⁷Lu-DKFZ-PSMA-617 in treatment of patients with castration resistant prostate cancer (#91)

8:30 AM

Sanjana Ballal

⁴⁴Sc-PSMA-617 for pre-therapeutic dosimetry of prostate cancer (#92)

8:30 AM

Elisabeth Eppard

Automated synthesis of ⁶⁸Ga-PSMA-11 using the Scintomics^® GRP module applying acetate buffer as an alternative to HEPES (#93)

8:30 AM

Rene Martin

One step kit labelling for PET imaging of prostate cancer using ⁶⁸Ga-THP-PSMA (#94)

8:30 AM

Philip J Blower

Requirements on Specific Activity (SA) of ¹⁷⁷Lu to Radiolabel DOTA-peptides for PRRT. Studies on Labeling a Typical Formulation of 0.1 mg DOTA-PSMA-617 (=0.1 µmoles) with 4 GBq ¹⁷⁷Lu at Various SA of ¹⁷⁷Lu (#95)

8:30 AM

Wouter AP Breeman

PSMA-11 in a dry kit formulation for ⁶⁸Ga labelling (#96)

8:30 AM

Renata Mikolajczak

Long-term evaluation of a ⁶⁸Ga-PSMA-11 kit radiolabeling procedure and performance assessment for imaging GCPII/PSMA expression in patients with breast and prostate cancer (#97)

8:30 AM

Janine Suthiram

Establishing a routine method for the manual labeling of PSMA-I&T and PSMA-617 with Lutetium-177 under GMP conditions   (#98)

8:30 AM

Harshad R Kulkarni